Pancreatic Ductal Adenocarcinoma - Pipeline Insight, 2024

This Pancreatic Ductal Adenocarcinoma - Pipeline Insight, 2024,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pancreatic Ductal Adenocarcinoma Understanding

Pancreatic Ductal Adenocarcinoma: Overview

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, with an average 5-year survival rate of less than 10%. Unfortunately, the majority of patients have unresectable, locally advanced, or metastatic disease at the time of diagnosis. PDAC development is associated with a poor prognosis due to its complicated and multifactorial nature. There is a lack of simple, early detection methods and is typically diagnosed at a late stage because symptoms do not appear until the disease has progressed and metastasized to distinct sites. The major difficulties in treating pancreatic cancer lie at both the genetic and cellular levels. The extent of mutational changes in pancreatic tumors generates gene instability that appears to play an essential role in PDAC tumor growth and resistance to treatments.

Pancreatic Ductal Adenocarcinoma - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pancreatic Ductal Adenocarcinoma pipeline landscape is provided which includes the disease overview and Pancreatic Ductal Adenocarcinoma treatment guidelines. The assessment part of the report embraces, in depth Pancreatic Ductal Adenocarcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Ductal Adenocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Pancreatic Ductal Adenocarcinoma. The therapies under development are focused on novel approaches to treat/improve Pancreatic Ductal Adenocarcinoma.
• In January 2022, Panbela Therapeutics announced the commencement of the Phase II ASPIRE clinical trial of SBP-101 plus gemcitabine and nab-paclitaxel to treat metastatic pancreatic ductal adenocarcinoma patients.

Pancreatic Ductal Adenocarcinoma Emerging Drugs

Onvansertib: Cardiff Oncology
Onvansertib, an oral highly-selective PLK1 inhibitor, which we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC.

Nadunolimab: Cantargia
Nadunolimab is a humanised monoclonal antibody lacking fucose, being developed by Cantargia, for the treatment of solid tumours, including non-small cell lung cancer (NSCLC) and pancreatic cancer. Nadunolimab is a first-in-class anti-IL1RAP antibody, currently evaluated with standard of care chemotherapy or checkpoint inhibitor in five phase I/II clinical trials with a primary focus on PDAC and NSCLC. Nadunolimab induces ADCC and blocks signaling of both IL-1a and IL-1ß, counteracting thecontribution of IL-1 to the immune suppressive tumor microenvironment and development of resistance to chemotherapy

Zimberelimab: Arcus Biosciences
Zimberelimab is a monoclonal antibody that binds pd-1 restoring the antitumor activity of T-cells. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with The most advanced study with zimberelimab is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic. Zimberelimab is also being evaluated as monotherapy in a tumor agnostic, biomarker-selected Phase 1b trial for cancers with no approved anti-PD-1 treatment options. full line-of-sight to the commercialization of innovative therapies for all patients who may benefit.

Pancreatic Ductal Adenocarcinoma: Therapeutic Assessment

This segment of the report provides insights about the Pancreatic Ductal Adenocarcinoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pancreatic Ductal Adenocarcinoma

There are approx. 80+ key companies which are developing the therapies Pancreatic Ductal Adenocarcinoma. The companies which have their Pancreatic Ductal Adenocarcinoma drug candidates in the most advanced stage, i.e phase III include XOMA

Phases

This report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pancreatic Ductal Adenocarcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pancreatic Ductal Adenocarcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pancreatic Ductal Adenocarcinoma drugs.

Pancreatic Ductal Adenocarcinoma Report Insights

• Pancreatic Ductal Adenocarcinoma Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pancreatic Ductal Adenocarcinoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pancreatic Ductal Adenocarcinoma drugs?
• How many Pancreatic Ductal Adenocarcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pancreatic Ductal Adenocarcinoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pancreatic Ductal Adenocarcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pancreatic Ductal Adenocarcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Cardiff Oncology
• XOMA
• Alphamab
• Cantargia
• RenovoRx
• Syntrix Biosystems
• Eucure Biopharma
• Panbela Therapeutics
• Jeil Pharmaceutical
• Elicio Therapeutics
• Cend Therapeutics
• SignalChem Lifesciences
• Bristol-Myers Squibb
• AstraZeneca
• REVOLUTION Medicines
• Arcus Biosciences
• ZielBio
• Surface Oncology
• Incyte Corporation
• I-Mab Biopharma
• Medicenna Therapeutics
• Tarveda Therapeutics

Key Products

• Onvansertib
• NIS 793
• Erfonrilimab
• Nadunolimab
• Gemcitabine
• SX 682
• YH 003
• SBP 101
• JPI-547
• ELI-002
• CEND 1
• SLC-0111
• BMS-813160
• Oleclumab
• RMC-6236
• Zimberelimab
• ZB131
• NZV930
• INCB106385
• TJ CLDN4B
• MDNA11
• Locnartecan

This product will be delivered within 1-3 business days.